These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 10517727)

  • 21. [Heparin in the treatment of unstable angina. Can the decrease of the molecular size increase its effectiveness?].
    Panchenko EP
    Ter Arkh; 1998; 70(12):71-4. PubMed ID: 10067259
    [No Abstract]   [Full Text] [Related]  

  • 22. [Efficacy and safety of low molecular weight heparin in the treatment of pulmonary thromboembolism].
    Cereza G; Danés I
    Med Clin (Barc); 1999 Jun; 113(3):115-6. PubMed ID: 10464747
    [No Abstract]   [Full Text] [Related]  

  • 23. ExTRACT-TIMI 25 in perspective: key lessons regarding enoxaparin as an adjunct to fibrinolytic therapy.
    Thomas D; Giugliano RP
    J Thromb Thrombolysis; 2009 Jan; 27(1):1-10. PubMed ID: 18931978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of unstable angina and myocardial infarction.
    Cohen M; Turpie AG
    Lancet; 2000 Sep; 356(9236):1193-4. PubMed ID: 11030322
    [No Abstract]   [Full Text] [Related]  

  • 25. Fondaparinux versus enoxaparin in acute coronary syndromes.
    Majure DT; Aberegg SK
    N Engl J Med; 2006 Jun; 354(26):2829; author reply 2830. PubMed ID: 16807423
    [No Abstract]   [Full Text] [Related]  

  • 26. The search for replacements for unfractionated heparin.
    Antman EM
    Circulation; 2001 May; 103(18):2310-4. PubMed ID: 11342482
    [No Abstract]   [Full Text] [Related]  

  • 27. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies.
    Spinler SA; Inverso SM; Cohen M; Goodman SG; Stringer KA; Antman EM;
    Am Heart J; 2003 Jul; 146(1):33-41. PubMed ID: 12851605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Role of low-molecular-weight heparin in acute coronary syndromes].
    Gharbi M; Barakett N; Lahidheb DH; Smiri Z; Fehri W; Azzouzi F; Rahal N; Mhenni H; Haouala H; Guediche M
    Tunis Med; 2002 Dec; 80(12):725-32. PubMed ID: 12664498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Newer antithrombin agents in acute coronary syndromes.
    Antman EM; Cohen M
    Am Heart J; 1999 Dec; 138(6 Pt 2):S563-9. PubMed ID: 10577463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A contemporary assessment of low-molecular-weight heparin for the treatment of acute coronary syndromes: factoring in new trials and meta-analysis data.
    Topol EJ
    Am Heart J; 2005 Apr; 149(4 Suppl):S100-6. PubMed ID: 16124950
    [No Abstract]   [Full Text] [Related]  

  • 31. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators.
    J Am Coll Cardiol; 1997 Jun; 29(7):1474-82. PubMed ID: 9180107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enoxaparin. A review of its clinical potential in the management of coronary artery disease.
    Noble S; Spencer CM
    Drugs; 1998 Aug; 56(2):259-72. PubMed ID: 9711450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dabigatran: new drug. Continue to use heparin, a better-known option.
    Prescrire Int; 2009 Jun; 18(101):97-9. PubMed ID: 19637411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in antithrombotic therapy in acute myocardial infarction: the ExTRACT-TIMI 25 and OASIS-6 Trials.
    Alexander JH; Harrington RA
    Curr Cardiol Rep; 2006 Jul; 8(4):279-81. PubMed ID: 16883666
    [No Abstract]   [Full Text] [Related]  

  • 35. Low-molecular-weight heparin and other antithrombotic agents in the setting of a primarily medical treatment of unstable coronary artery disease.
    Verheugt FW
    Haemostasis; 2000; 30 Suppl 2():122-7; discussion 106-7. PubMed ID: 11251355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Fernandez JS; Sadaniantz A
    Med Health R I; 2001 Feb; 84(2):37-43. PubMed ID: 11272658
    [No Abstract]   [Full Text] [Related]  

  • 37. The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
    Becker RC
    Am Heart J; 2005 Aug; 150(2):189-92. PubMed ID: 16086916
    [No Abstract]   [Full Text] [Related]  

  • 38. [Low-molecular-weight heparin in deep venous thrombosis. Dosage for all weight classes].
    MMW Fortschr Med; 2003 Jun; 145(24):56. PubMed ID: 12866309
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical benefit of enoxaparin in patients with high-risk acute coronary syndromes without ST elevations in clinical practice.
    Zeymer U; Gitt A; Jünger C; Koeth O; Zahn R; Wienbergen H; Gottwik M; Senges J;
    Am J Cardiol; 2006 Jul; 98(1):19-22. PubMed ID: 16784913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of venous thrombosis.
    Hirsh J
    Haemostasis; 1996 Oct; 26 Suppl 4():189-98. PubMed ID: 8979124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.